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Abstract
Introduction:  Metabolic  syndrome  is  an  emerging  problem  in  developed  countries  and  presents
itself as  a  potential  threat  worldwide.  The  role  of  diabetes,  dyslipidaemia  and  hepatic  steato-
sis as  pivotal  components  of  the  metabolic  syndrome  is  well  known.  However,  their  common
persistent  chronic  inﬂammation  and  its  potential  cause  still  elude.  This  systematic  review  aims
to present  evidence  of  the  mechanisms  that  link  the  intestinal  microbioma,  innate  immunity
and metabolic  syndrome.
Methods:  A  comprehensive  research  was  made  using  PubMed  database  and  35  articles  were
selected.
Results: We  found  that  metabolic  syndrome  is  associated  to  increased  levels  of  innate  immunity
receptors, namely,  Toll-like  receptors,  both  in  intestine  and  systemically  and  its  polymorphisms
may change  the  risk  of  metabolic  syndrome  development.  Microbioma  dysbiosis  is  also  present
in metabolic  syndrome,  with  lower  prevalence  of  Bacteroidetes  and  increased  prevalence  of
Firmicutes populations.  The  data  suggest  that  the  link  between  intestinal  microbiota  and  Toll-
like receptors  can  negatively  endanger  the  metabolic  homeostasis.
Conclusion:  Current  evidence  suggests  that  innate  immunity  and  intestinal  microbiota  may  be
the hidden  link  in  the  metabolic  syndrome  development  mechanisms.  In  the  near  future,  this
can be  the  key  in  the  development  of  new  prophylactic  and  therapeutic  strategies  to  treat
metabolic  syndrome  patients.uesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
cle  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/© 2015  Sociedade  Portug
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Revisão  Sistemática  da  Relac¸ão Entre  a  Microbiota  Intestinal  e  os  Receptores  Toll-Like
na  Síndrome  Metabólica:  O  Que  Sabemos  Atualmente?
Resumo
Introduc¸ão:  A  síndrome  metabólica  é,  hoje,  um  problema  emergente  nos  países  desenvolvidos
e apresenta-se  como  uma  das  principais  ameac¸as  médicas  à  escala  global.  O  papel  desempen-
hado pela  diabetes,  dislipidemia  e  a  esteatose  hepática,  como  componentes  principais  desta
Síndrome é  prontamente  reconhecido.  No  entanto,  a  inﬂamac¸ão  crónica  persistente  comum  e
as suas  potenciais  causas  ainda  não  estão  claramente  deﬁnidas.
Objectivos:  Esta  revisão  sistemática  pretende  apresentar  evidências  dos  mecanismos  que
interligam  o  microbioma  intestinal,  a  imunidade  inata  e  a  síndrome  metabólica.
Métodos:  Uma  pesquisa  sistemática  foi  realizada,  utilizando  a  base  de  dados  PubMed,  tendo
selecionado  35  artigos  para  a  elaborac¸ão  desta  revisão.
Resultados:  A  síndrome  metabólica  está  claramente  associada  a  níveis  aumentados  de
expressão dos  receptores  da  imunidade  inata,  nomeadamente,  os  receptores  da  família  Toll-like
receptors,  quer  no  tecido  intestinal,  quer  sistemicamente,  e  diferentes  polimorﬁsmos  parecem
ser responsáveis  por  diferentes  riscos  de  desenvolver  esta  doenc¸a.  Por  outro  lado,  a  disbiose
do microbioma  intestinal  está  também  presente  na  síndrome  metabólica,  com  a  presenc¸a  de
Bacteriodetes  em  menor  prevalência  e  com  aumento  das  populac¸ões  de  Firmicutes.  Os  result-
ados sugerem  ainda  que  a  ligac¸ão  entre  a  microbiota  intestinal  e  os  receptores  da  imunidade
inata possa  negativamente  comprometer  a  homeostasia  metabólica,  de  forma  semelhante  à
evidenciada  nesta  síndrome.
Conclusões:  Evidência  actual  sugere  e  suporta  que  a  imunidade  inata  e  a  microbiota  intestinal
possam ser  a  ligac¸ão  pivô  nos  mecanismos  de  desenvolvimento  da  síndrome  metabólica.  Num
futuro próximo,  esta  pode  ser  a  chave  para  o  desenvolvimento  de  novas  estratégias  proﬁláticas
e terapêuticas  para  a  síndrome  metabólica.
©  2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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conditions  used,  difference  in  means  of  RNA  or  biochemical1. Introduction
The  metabolic  syndrome  presents  itself  as  one  as  the  prin-
cipal  chronic  diseases  of  the  developed  countries  and  an
important  determinant  of  cardiovascular  and  metabolic
mortality  risk.1 It  is  deﬁned  as  a  persistent  pro-inﬂammatory
state  in  which  abnormal  metabolic  and  physiological  factors
produce  an  increased  risk  of  developing  diabetes,  obe-
sity,  dyslipidaemia  and  other  cardiovascular  risk  factors.1--3
Recent  data  report  a  consistent  activation  of  the  innate
immunity  through  the  Toll-like  receptors  (TLR)  and  its  down-
stream  signalling,  suggesting  not  only  a  potential  causative
way,  but  also  a  possible  perpetuator  of  its  chronic  immune
stress  to  the  organism.4--6 On  the  other  hand,  new  insights
have  revealed  a  pivotal  role  of  the  intestinal  microbiota
and  its  interaction  with  the  host  genetics,  in  the  develop-
ment  of  obesity  and  insulin  resistance.7--9 It  has  been  also
described  in  the  role  of  intestinal  microbiota,  its  migration
and  its  metabolic  products  systemic  effects,  in  the  activa-
tion  of  these  TLR  receptors  in  several  organs,  especially  the
liver.10,11
However,  in  spite  of  this  new  data,  the  relationship,
causality  and  the  mechanisms  by  which  the  intestinal
microbiota  can  inﬂuence  the  expression  of  several  immune
receptors  including  TLR  still  eludes.  Also,  the  relationship
between  differential  expression  of  TLR  and  the  lesion  of
several  organs  presented  in  metabolic  syndrome  is  poorly
understood.
e
t
iThis  systematic  review  aims  to  access  the  most  recent
ata  about  the  relevance  of  intestinal  microbiota  and
LR  expression  in  the  development  of  hepatic  lesion  and
etabolic  syndrome.
.  Methods
 comprehensive  search  was  performed  in  PubMed  and  the
ollowing  queries  were  used:  [(‘‘Metabolic  Syndrome’’[All
ields]  AND  (‘‘microbiome’’[All  Fields]  OR  ‘‘microbiota’’[All
ields]))  OR  (‘‘Metabolic  Syndrome’’[All  Fields]  AND  (‘‘Toll-
ike  receptors’’[All  Fields]  OR  ‘‘TLRs’’[All  Fields])  AND
‘‘microbiome’’[All  Fields]  OR  ‘‘microbiota’’[All  Fields]))],
nd  [(gut  microbiota[Title]  OR  microbiota[Title])  AND
((TLR[Title])  OR  Toll  like  receptor[Title])  OR  Innate  immu-
ity[Title])].
From  the  search  and  after  duplicates  were  removed,  230
tudies  were  retrieved  (Fig.  1).  Using  inclusion  and  exclusion
riteria,  35  articles  were  selected,  analyzed  and  included  in
his  revision  (Table  1).
The  principal  summary  measures  in  an  outcome  level
ere  different  risk  ratios  of  developing  obesity,  diabetes,
yslipidaemia  or  metabolic  syndrome  in  every  experimentalxpression  levels  of  markers  studied  and  differences  on  his-
ological  or  phenotypical  assessment  of  major  organs  studied
n  a  variety  of  experimental  conditions.  Subgroup  analyses
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•  (1) revision articles
•  (2) studies considered by
the authors as unrelated
to the principal mesh
terms of the theme
•  (1) studies that had its publication data until June of 2014,
•  (2) studies which experimental or revision data were found to have relevance to this article
•  (3) clinical trials and experimental studies using metabolic syndrome mice models study
selection and data collection process
Exclusion criteria:
Inclusion criteria:
•  (1) studies considered by
the authors as unrelated
to the principal mesh
terms of the theme 
•  (2) studies using
neoplastic assessment
outcomes
Exclusion criteria:
Articles identified
through database
searching
(n=234)
Added articles from
cross-referencing
(n=5 articles)
Articles after duplicates removed
(n=230 studies)
Articles screened
(n=230)
Full-text articles
assessed for eligibility
(n=53)
Rejected articles using
exclusion criteria
(n=18)
Studies included in
qualitative synthesis
(n=35)
Rejected articles using
exclusion criteria
(n=187)
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sFigure  1  Fluxogram  describing  the  met
ithin  the  selected  studies  were  also  considered  and  taken
nto  account.
. TLR expression and metabolic syndrome:
he importance of the innate immunity
t  is  well  known  that  the  TLRs  comprehend  an  extended  fam-
ly  of  pathogen-associated  molecular  patterns  recognition
PAMP)  receptors  of  the  innate  immunity.  These  recep-
ors  allow  the  prompt  activation  of  downstream  signalling
f  MyD88-dependent  and  MyD88-independent  pathways  in
esponse  to  several  antigens,  mainly  of  Gram-positive  and
ram-negative  bacteria,  and  they  are  all  linked  to  produc-
ion  of  cytokines  and  enhancement  of  the  inﬂammation.
Since  it  is  established  that  subclinical  inﬂammatory
rocesses  are  major  contributors  to  metabolic  syndrome,
besity  and  diabetes,  several  lines  of  investigation  were
ade  to  conﬁrm  the  role  of  innate  immunity  receptors
nd  prompt  activation  in  the  pathogenesis  of  metabolic
isturbances.12
An  initial  study  shows  that  there  was  a  signiﬁcant  increase
n  both  TLR2  and  TLR4  cell  surface  expression  and  mRNA
evels  in  monocytes  of  metabolic  syndrome  patients.  This
henomenon  persisted  even  when  its  values  were  statisti-
ally  adjusted  to  waist  circumference  and  body  mass  index.
his  study  also  reveals  that  this  TLR  increased  activity  was
igniﬁcantly  correlated  with  signiﬁcant  higher  blood  pres-
ure  and  plasma  glucose  levels,  and  with  interleukin-1b
s
l
p of  data  collection  and  articles  selection.
IL-1b),  Monocyte  Chemoattractant  Protein-1  (MCP-1)  and
ecrosis  Factor-kB  (NF-kB)  activity,  concluding  that  the  acti-
ation  of  the  TLR  can  count  as  an  independent  factor  not
nly  to  metabolic  syndrome  but  also  to  the  cardiovascular
isk  of  these  patients.13
The  impact  of  TLRs  is  also  veriﬁed  in  other  clinical
ituations  that  are  strongly  related  to  metabolic  syndrome
nd  that  can  explain  its  participation  as  a  causative  factor
hrough  indirect  pathways.
On  one  hand,  Cristina  Cuda  et  al  showed  that  differ-
nt  polymorphisms  of  TLR4,  with  different  activation  rates
f  this  receptor,  were  statistically  associated  to  different
erum  insulin  levels  and  insulin  sensitivities.  The  individ-
als  with  TLR4  with  299Gly  allele  were  found  to  have  higher
evels  of  insulin  and  lower  levels  of  insulin  sensitivity  in  com-
arison  to  the  considered  normal  Asp  homozygotes.  They
lso  found  that  a  second  polymorphism,  an  intronic  SNP
rs5030728)  can  even  modulate  the  relationship  between
ietary  saturated  fatty  acids  and  HDL  cholesterol,  show-
ng  that  an  increased  intake  of  saturated  fatty  acids  was
nversely  related  to  signiﬁcant  lower  levels  of  HDL  choles-
erol,  in  these  individuals.14 Steinhardt  et  al,15 on  the  other
and,  strongly  conﬁrmed  that  another  polymorphism  of  TLR4
s  associated  to  syndromes  of  lipid  accumulation,  thereby
ustaining  that  TLR  could  be  involved  in  the  regulation  of
everal  metabolically  substrates  and  increase  the  risk  of  dys-
ipidaemia,  a  known  factor  related  to  metabolic  syndrome.
Another  line  of  evidence  using  mice  with  +3725G/C
olymorphism  of  TLR4,  shows  that  these  mice  have  a
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Table  1  Main  characteristics  of  animal  and  clinical  studies  included  in  the  systematic  revision.
Title Authors  Year Type  of  study Methods  Limitations  Main  conclusions
Polymorphisms  in
Toll-like  receptor  4  are
associated  with  factors
of the  Metabolic
Syndrome  and  modify
the  association
between  dietary
saturated  fat  and
fasting  high-density
lipoprotein  cholesterol
Cristina  Cuda
et  al.
2010  Prospective
cohort  study
-- Dietary  assessment
-- Anthropometrics
and  energy
expenditure
assessment
-- Genotyping  using
PCR
-- Very  homogeneous
study  population
-- Exclusion  of
individuals  from  the
study  population  with
comorbidities
associated  to
Metabolic  Syndrome
-- Carriers  of  the  Asp299Gly
polymorphism  had  signiﬁcantly  higher
insulin  levels,  higher  homeostasis  model
assessment  of  insulin  resistance  and
family  history  of  diabetes
-- Carriers  of  the  intronic  polymorphism
(rs5030728)  modiﬁed  the  relationship
between  dietary  SFA  and  HDL  cholesterol
A functional
nonsynonymous
Toll-like  receptor  4
gene  polymorphism  is
associated  with
Metabolic  Syndrome,
surrogates  of  insulin
resistance,  and
syndromes  of  lipid
accumulation
Alberto  Penas
Steinhardt
et al.
2010  Cross  sectional
study
-- Clinical
measurements
-- Genotyping  using
PCR
-- All  individuals
included  in  the  study
were  men.
-- Individuals  with
comorbidities
associated  to
Metabolic  Syndrome
were  not  included
-- Carriers  of  Asp299Asp  Tlr4
polymorphism  had  higher  prevalence  of
enlarged  waist  elevated  triglyceride
syndrome,  hypertriglyceridaemic  waist
(HW),  and  overweight-lipid  syndrome
-- Carriers  of  Asp299Asp  Tlr4
polymorphism  had  higher  insulin  levels,
and were  associated  to  Metabolic
Syndrome  in  the  group  of  individuals
with  C-reactive  protein  levels  below  the
95th  percentile
Functional
characterization  of
TLR4  +3725  G/C
polymorphism  and
association  with
protection  against
overweight
Alberto  Penas
Steinhardt
et al.
2012  Prospective
cohort  study
--  Genotyping  using
PCR
-- Cell  culture  and
transfections
-- Biochemical
analyses,
anthropometric  and
clinical
measurements
--  No  exclusion
criteria  were  used
--  Carriers  of  11350G/C  TLR4
polymorphism  were  associated  to  a
reduction  of  30%  of  TLR4  gene  activity
--  Carriers  of  11350G/C  TLR4
polymorphism  had  also  less  weight,
lower  BMI,  waist  circumference  and
higher  adiponectine  levels
The Asp299Gly
polymorphism  alters
TLR4  signalling  by
interfering  with
recruitment  of  MyD88
and  TRIF
Leandra
Figueiroa  et  al.
2012  Experimental
study
-- Cell  culture  and
transfections
-- RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
-- Antagonists  of  the
TLR4-MyD88  were  not
studied
-- Mice  that  carried  D299G  polymorphism
of the  TLR4  revealed  comparable  total
TLR4 expression,  TLR4--MD2
interactions,  and  LPS  binding,  in
comparison  to  wild  type  mice.  However,
they  were  associated  to  macrophages
that failed  to  elicit  LPS-mediated
induction  of  TNF-  and  IFN-b  mRNA
levels  and  diminished  LPS-driven
interaction  of  MyD88  and  TRIF  with  TLR4
244
 
J.P.
 Portela-Cidade
 et
 al.
Table  1  (Continued)
Title  Authors  Year  Type  of  study  Methods  Limitations  Main  conclusions
Toll-like  receptor  4
D299G  polymorphism
in metabolic  disorders:
a  meta-analysis
Belforte  et  al.  2012  Meta-analysis  --  --  Possible  publication
bias
--  Low  number  of
studies  included
--  A  signiﬁcant  association  between  TLR4
D299G  polymorphism  and  metabolic
disorders  (T2DM  and  Met-S)  risk
(OR =  0.566,  95%  CI:  0.347--0.925,
p =  0.023)  particularly  in  Caucasians  was
reported
Innate immunity  and
intestinal  microbiota
in  the  development  of
type  1  diabetes
Li  Wen  et  al.  2008  Experimental
study
--  Histopathology
evaluation
--  Sequencing  and
phylogenetic  analysis
--  Other  parallel
signalling  pathways
such  as  TRIF  were  not
considered
--  Speciﬁc-pathogen-free  (SPF)
non-obese  diabetic  mice  lacking  MyD88
protein  did  not  develop  type  1  diabetes
-- MyD88-deﬁciency  changes  the
composition  of  the  distal  gut  microbiota
-- The  exposure  to  the  microbiota  of
Speciﬁc  pathogen-free
NOD.MyD88-negative  donors  attenuates
type  1  diabetes  found  in  germ  free  NOD
recipients
Toll-like receptor
2-deﬁcient  mice  are
protected  from  insulin
resistance  and  beta
cell  dysfunction
induced  by  a  high-fat
diet
Ehses  et  al.  2009  Experimental
study
--  Indirect  calorimetry
and  physical  activity
assessment
-- Immunohistochem-
istry
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Inability  to
conclude  whether  the
observed  reductions
in  tissue
inﬂammation  in  vivo
are  due  to  an  immune
cell,  or  parenchymal
cell  origin
--  Mice  with  Tlr2−/−  genotype  were
protected  from  the  adverse  effects  of
high-fat  diet  compared  with  Tlr2+/+
littermate  controls
--  Female  Tlr2−/−  mice  showed
pronounced  improvements  in  glucose
tolerance,  insulin  sensitivity,  and  insulin
secretion  following  20  weeks  of  HFD
feeding
Toll-like receptor  2
deﬁciency  improves
insulin  sensitivity  and
hepatic  insulin
signalling  in  the  mouse
Kuo  et  al.  2010  Experimental
study
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Protein  analysis
--  Further  studies  are
needed  to  account
for  the  mechanistic
insight  of  the
improvement  of
insulin  sensitivity
with  TLR2  deﬁciency
--  Aged  or  high-fat-fed  TLR2-deﬁcient
mice  were  protected  from  obesity  and
adipocyte  hypertrophy  compared  with
wild-type  mice
--  Mice  lacking  TLR2  exhibited  improved
glucose  tolerance  and  insulin  sensitivity
regardless  of  feeding  them  regular  chow
or a  high-fat  diet
-- The  attenuated  hepatic  inﬂammatory
cytokine  expression  and  related
signalling  are  correlated  with  increased
insulin  action  speciﬁcally  in  the  liver  in
TLR2-deﬁcient  mice
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Table  1  (Continued)
Title Authors  Year Type  of  study Methods  Limitations  Main  conclusions
Familial  transmission
rather  than  defective
innate  immunity
shapes  the  distinct
intestinal  microbiota
of  TLR-deﬁcient  mice
Carles  Ubeda
et  al.
2012  Experimental
study
-- High-throughput
sequencing  of  16S
rRNA  genes
-- RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Environmental
intestinal
colonization  besides
maternal  origin  was
not  studied
--  The  composition  of  intestinal  microbiota
was not  signiﬁcantly  different  between
MyD88-,  TLR2-,  TLR4-,  TLR5-,  and
TLR9-deﬁcient  mice  and  their  respective
wild-type  (WT)  littermates
-- Differences  between  different  knockout
mice  groups  were  due  to  long  term
divergence  in  isolation  from  each  other;
-- The long-term  differences  in  intestinal
microbiota  composition  resulted  mainly
from maternal  transmission
Metabolic Syndrome  and
altered  gut  microbiota
in  mice  lacking
Toll-like  receptor  5
Vijay-Kumar
et  al.
2010  Experimental
study
-- Bacterial
translocation  to
experimental
purposes
-- RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
Other  potential
correlations  with
other  TLR  were  not
considered  limiting
the  rational  for  TLR5
role  and
preponderance
Toll-like  receptor  5  knockout  mice
exhibited  hyperphagia,  hyperlipidaemia,
hypertension,  insulin  resistance,  and
increased  adiposity
-- Transfer  of  the  gut  microbiota  from
TLR5-deﬁcient  mice  to  wild-type  germ-free
mice  conferred  many  features  of  Metabolic
Syndrome  to  the  recipients
Colonic mucosal  DNA
methylation,  immune
response,  and
microbiome  patterns
in Toll-like  receptor
2-knockout  mice
Richard
Kellermayer
et  al.
2011  Experimental
study
-- Histological
assessment
-- Pyrosequencing
-- RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
-- Intestinal
microbiome  changes
were  not  as
reproductive  on
human  tissue  colonic
samples
-- In  the  TLR2  knockout  mice,  the
expression  of  genes  involved  in  immune
processes  were  found  signiﬁcantly  different
as  well  as  epigenomic  and  transcriptomic
modiﬁcations  associated  with  altered
microbiota  composition
-- Several  bacterial  species,  including
members  of  the  Firmicutes  were
signiﬁcantly  different  in  abundance
between  WT  and  Tlr2−/−  animals
A human  gut  microbial
gene  catalogue
established  by
metagenomic
sequencing
Junjie  Qin
et  al.
2010  Prospective
cohort  study
--  Stool  sampling
--  Real-time
quantitative  PCR
--  Library  database
construction
--  Only  usage  of
faecal  samples
--  Over  99%  of  the  genes  are  bacterial,
indicating  that  the  entire  cohort  harbours
between  1000  and  1150  prevalent  bacterial
species  and  each  individual  at  least  160
such  species,  which  are  also  largely  shared
--  This  Large  intestinal  microbiome  is
responsible  of  several  functions  known  to
be important  to  the  host--bacterial
interaction,  such  as  degradation  of  complex
polysaccharides,  synthesis  of  short-chain
fatty  acids,  indispensable  amino  acids  and
vitamins
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Title  Authors  Year  Type  of  study  Methods  Limitations  Main  conclusions
Microbiota  and
epigenetic  regulation
of  inﬂammatory
mediators  in  type  2
diabetes  and  obesity
Remely  et  al.  2014  Experimental
study
--  Pyrosequencing
--  RNA  isolation,  reverse
transcription,  and
real-time  quantitative  PCR
--  The  groups  were
not  entirely
comparable  by
possible  confounders
in  the  selection  of
mice  characteristics
--  Higher  ratio  of
Firmicutes/Bacteroidetes  in  type  2
diabetics  was  observed  when  compared
to lean  controls  and  obese,  as  well  as
lactic acid  bacteria
--  Methylation  analysis  of  four  CpGs  in
the ﬁrst  exon  of  TLR4  showed
signiﬁcantly  lower  methylation  in  obese
individuals  and  methylation  of  seven
CpGs  in  the  promoter  region  of  TLR2  was
signiﬁcantly  lower  in  type  2  diabetics
mice
-- The  methylation  levels  of  both  TLRs
were  signiﬁcantly  correlated  with  body
mass  index
Interactions between  gut
microbiota,  host
genetics  and  diet
relevant  to
development  of
Metabolic  Syndromes
in  mice
CHenhong
Zhang  et  al.
2010  Experimental
study
--  Pyrosequencing
--  RNA  isolation,  reverse
transcription,  and
real-time  quantitative  PCR
The  Biﬁdobacteria
effects  were  not
analyzed  since  this
group  of  bacteria  was
actually  removed
from  guts  fed  with
high-fat  diet  possibly
due  to  the  much
longer  feeding  time
--  Diet  changes  explained  57%  of  the
total  structural  variation  in  gut
microbiota  whereas  genetic  mutation
accounted  for  no  more  than  12%
-- Desulfovibrionaceae  were  dominant  in
all animals  with  impaired  glucose
tolerance,  most  signiﬁcantly  in  the
wild-type  with  high-fat  diet  group,
which  had  the  highest  calorie  intake  and
the most  serious  MS  phenotypes
Modulation of  gut
microbiota  during
probiotic-mediated
attenuation  of
metabolic  syndrome  in
high-fat  diet-fed  mice
Jingjing  Wang
et  al.
2014  Experimental
study
--  Enzyme-linked
immunosorbent  assay
-- Histomorphology  and
immunohistochemistry
-- Pyrosequencing
--  RNA  isolation,  reverse
transcription,  and
real-time  quantitative  PCR
--  Only  usage  of
faecal  samples
--  The  use  of  the  probiotics  was
responsible  for  a  reduction  of  the
bacteria  positively  related  to  Metabolic
Syndrome
-- A  probiotic  composed  by
Biﬁdobacterium  animalis  subsp.  lactis
I-2494  was  even  responsible  by  a
decreased  adipose  and  hepatic  TNF-
gene  expression
Transfer of  intestinal
microbiota  from  lean
donors  increases
insulin  sensitivity  in
individuals  with
Metabolic  Syndrome
Anne  Vrieze
et  al.
2012  Prospective
cohort  study
--  Gut  microbiota  transfer
procedures
--  RNA  isolation,  reverse
transcription,  and
real-time  quantitative  PCR
--  Biochemical  analysis  of
faecal  samples
--  Diet  composition
was  not  controlled  in
healthy  control
patients
--  After  infusion  of  microbiota  from  lean
donors,  all  groups  presented  an  increase
in insulin  sensitivity  of  recipients  and  an
increase  of  butyrate-producing  intestinal
microbiota
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Table  1  (Continued)
Title Authors  Year Type  of  study Methods  Limitations  Main  conclusions
Increased  Toll-like
receptor  activity  in
patients  with
Metabolic  Syndrome
Ishwarlal  Jialal
et  al.
2012  Prospective
cohort  study
-- Magnetic  cell
separation
-- RT-PCR
-- Fluorescent  in  situ
hybridization
-- The  control  group
could  have  less  than  2
features  of  Metabolic
Syndrome
-- Potential
differences  in  other
cells  expression
-- Circulating  levels  of  high-sensitivity
C-reactive  protein,  interleukin  (IL)-1b,
IL-6,  IL-8,  and  soluble  Tumour  Necrosis
Factor  receptor  1  (sTNFR1)  were
signiﬁcantly  increased  in  MetS  versus
control  subjects
-- Signiﬁcant  increase  in  both  TLR2  and
TLR4  surface  expression  and  mRNA  on
monocytes  after  adjustment  for  waist
circumference.
-- Plasma  free  fatty  acids  and  endotoxin
were  increased  in  Metabolic  Syndrome
patients  but  only  correlated  signiﬁcantly
considering  TLR4  expression
The inﬂuence  of
probiotic
supplementation  on
gut permeability  in
patients  with
Metabolic  Syndrome:
an  open  label,
randomized  pilot  study
Leber  et  al. 2012  Randomized
pilot  study
-- Fluorescent  in  situ
hybridization
-- Cytometric  analysis
-- Determination  of
endotoxin  excluding
important  pathogens
present  in  human  gut
-- Gut  permeability  was  signiﬁcantly
increased  in  Metabolic  Syndrome
compared  with  controls
--  LBP  and  sCD14  levels  were  not
signiﬁcantly  different  from  healthy
controls
-- High-sensitive  C-reactive  protein  and
LBP levels  slightly  but  signiﬁcantly
increased  after  3  months  within  the
probiotics  group
-- Neutrophil  function  and  TLR
expression  did  not  differ  from  healthy
controls  or  within  the  patient  groups
Augmented hepatic
Toll-like  receptors  by
fatty  acids  trigger  the
pro-inﬂammatory
state  of  non-alcoholic
fatty  liver  disease  in
mice
Koji  Sawada
et  al.
2014  Experimental
study
--  Cell  culture
--  Biochemical
analyses
--  Histopathological
evaluation
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Immunohistochem-
istry/immunocytochemistry
--  The  intestinal
microbiome  was
neither  characterized
nor  its  potential  role
in the  results
obtained
--  The  expression  of  inﬂammatory
cytokines  such  as  TNF,  IL-1,  and  TLR-2,
-4, -5,  and  -9  was  increased  in  the  liver,
but decreased  in  the  small  intestine  of
high-fat  diet-fed  mice  in  vivo
--  The  expression  of  TLRs  in  primary
hepatocytes  and  Kupffer  cells  was
increased  by  treatment  with  palmitic
acid
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Title  Authors  Year  Type  of  study  Methods  Limitations  Main  conclusions
Toll-like  receptor-4
mediates
obesity-induced
non-alcoholic
steatohepatitis
through  activation  of
X-box  binding
protein-1  in  mice
Dewei  Ye  et  al.  2014  Experimental
study
--  Cell  culture
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Use  of  a  new
understudied  mice
model  for
representation  of
human  NASH
--  The  model  used  with  a  high  fat  and  high
calorie  diet  developed  typical  pathological
features  of  NASH,  which  is  associated  with
obesity  and  the  Metabolic  Syndrome
-- Mice  lacking  functional  TLR4  were
resistant  to  HFHC  diet-induced  liver
inﬂammation  and  injury  and  were  less
susceptible  to  the  diet-induced  production
of reactive  oxygen  species  (ROS)  and
proinﬂammatory  cytokines
-- A transcription  factor  XBP-1  involved  in
the unfolded  protein  responses,  was
activated  in  the  liver  by  an  HFHC  diet,
whereas  XBP-1  activation  was  abrogated  in
TLR4  knockout  mice
Toll-like receptors  1--9
are  elevated  in  livers
with  fructose-induced
hepatic  steatosis
Sabine
Wagnerberger
et  al.
2012  Experimental
study
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
-- Immunostaining  and
histology  evaluation
--  Western  blotting
--  Mechanisms  of
hepatic  TLR
activation  were  not
studied
--  The  accumulation  of  triacylglycerol  found
in the  livers  of  fructose-fed  mice  was
associated  to  a  signiﬁcant  induction  of
TLR1--4  and  6--8.
-- Plasma  RBP4  concentration  and  hepatic
mRNA  expression  levels  of  TNF-,  iNOS,
MyD88  and  number  of  F4/80  positive  cells
of fructose-fed  animals  were  signiﬁcantly
higher  than  those  of  controls
--  These  effects  of  fructose  were
attenuated  in  antibiotic-treated  mice
Inﬂammasome-mediated
dysbiosis regulates
progression  of  NAFLD
and  obesity
Jorge
Henao-Mejia
et  al.
2012  Experimental
study
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
-- Immunostaining  and
histology  evaluation
--  Transmission
electron  microscopy
--  Bacterial  16S  rRNA
amplicon  sequencing
--  False  negative  and
false  positive  results
could  be  allocated  to
the  measure  of  PAMPs
method  used
--  Inﬂammasome  deﬁciency-associated
changes  in  the  conﬁguration  of  the  gut
microbiota  are  associated  with  exacerbated
hepatic  steatosis  and  inﬂammation  through
inﬂux  of  TLR4  and  TLR9  agonists  and
enhanced  hepatic  TNF-
--  Co-housing  of  inﬂammasome-deﬁcient
animals  to  wild  type  mice  results  in
exacerbation  of  hepatic  steatosis,  glucose
intolerance,  and  obesity
-- NLRP3  and  NLRP6  inﬂammasomes  govern
the rate  of  progression  of  multiple
Metabolic  Syndrome-associated
abnormalities
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Table  1  (Continued)
Title Authors  Year Type  of  study Methods  Limitations  Main  conclusions
Probiotics  antigens
stimulate  hepatic  NKT
cells
Shuwen  Liang
et  al.
2013  Experimental
study
-- Histology
-- Flow  cytometry
-- Immunoﬂuores-
cence  expression
assessment
--  NKT  cells  participation  in  the
development  of  NASH  was  not
clear
--  High  dose  of  selected  probiotic  was
effective  for  the  improvement  of  hepatic
NKT  cell  depletion,  obesity  and  steatosis
-- Disruption  of  TLR4  signalling  does  not
protect  HF  diet  induced  NKT  cell
depletion  and  metabolic  dysfunction
Intestinal microbiota  and
innate
immunity-related  gene
alteration  in  cirrhotic
rats  with  liver
transplantation
Xie  et  al. 2011  Experimental
study
-- RNA  isolation,
reverse
transcription,  and
real-time
quantitative  PCR
-- Bacterial
translocation  for
experimental
groups  protocol
-- The  experimental  model
acquisition  method  could
inﬂuence  intestinal  bacteria
directly  and  inﬂuence  its
modiﬁcations
-- Liver  cirrhosis  and  liver  cirrhosis  with
transplant  were  associated  to  higher
endotoxin  levels  and  with  higher
incidence  of  bacterial  translocation  to
liver  and  mesenteric  lymph  nodes,  and
with the  number  of  total  bacteria
-- Mucins  (MUC2,  MUC3)  and  Toll-like
receptors  (TLR2,  TLR4)  messenger  RNA
(mRNA)  expression  were  signiﬁcantly
higher  in  the  cirrhosis  groups  than  the
control  group
Diversity of  the  human
intestinal  microbial
ﬂora
Paul  Eckburg
et  al.
2005  Case--control
study
-- RNA  isolation,
reverse
transcription,  and
real-time
quantitative  PCR
--  Pyrosequencing  as  the  most
accurate  method  of  bacterial
identiﬁcation  was  not  used
--  A  majority  of  the  bacterial  sequences
corresponded  to  uncultivated  species
and  novel  microorganisms
-- Signiﬁcant  intersubject  variability  and
differences  between  stool  and  mucosa
community  composition  were  observed
The gut  microbiota  as  an
environmental  factor
that  regulates  fat
storage
Fredrik
Bäckhed  et  al.
2004  Experimental
study
-- Measurement  of
total  body  fat
content  and
metabolic  rate
-- RNA  isolation,
reverse
transcription,  and
real-time
quantitative  PCR
-- Microbiota  composition  was
not  accessed
-- Adult  germ-free  mice  with  a  normal
microbiota  harvested  from  the  distal
intestine  (cecum)  of  conventionally
raised  animals  produces  a  60%  increase
in body  fat  content  and  insulin
resistance  despite  reduced  food  intake.
-- Microbiota  promotes  absorption  of
monosaccharides  from  the  gut  lumen,
with  resulting  induction  of  de  novo
hepatic  lipogenesis
Mechanisms underlying
the  resistance  to
diet-induced  obesity
in  germ-free  mice
Fredrik
Ba¨ckhed  et  al.
2007  Experimental
study
--  Immunoblotting
--  RNA  isolation,
reverse
transcription,  and
real-time
quantitative  PCR
--  The  bacterial  microbiota  was
not  assessed  or  characterized
and  could  explain  for  the
differences  observed  in
Fiaf-deﬁcient  mice
--  The  preponderance  of
mechanisms  in  the  explanation
of the  increased  obesity  was
not ascertained  statistically
--  Germ-free  mice  were  associated  with
a lean  phenotype  and  increased  levels  of
AMPK  expression  in  liver  and  muscle
samples
-- Knockout  mice  lacking  fasting-induced
adipose  factor  are  not  protected  from
diet-induced  obesity
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Title  Authors  Year  Type  of  study  Methods  Limitations  Main  conclusions
Human  gut  microbes
associated  with
obesity
Ruth  et  al.  2006  Prospective
cohort  study
--  Pyrosequencing
--  Real-time
quantitative  PCR
--  Low  number  of
participants  in  the
study
--  Bacterial  lineages  were  remarkably
constant  within  people  over  time
-- Before  diet  therapy,  obese  people  had
fewer  Bacteroidetes  (P  <  0.001)  and  more
Firmicutes  (P  =  0.002)  than  did  lean  controls
-- With  time,  the  relative  abundance  of
Bacteroidetes  increased  (P  <  0.001)  and  the
abundance  of  Firmicutes  decreased
(P  =  0.002),  irrespective  of  diet  type
Deﬁciency in  myeloid
differentiation
factor-2  and  Toll-like
receptor  4  expression
attenuates
nonalcoholic
steatohepatitis  and
ﬁbrosis  in  mice
Timea  Csak
et  al.
2011  Experimental
study
--  Histological
evaluation
--  Flow  cytometry
analysis
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  Participation  of
other  TLR  that  could
account  for  the
results  obtained  were
not  considered
--  Features  of  NASH  were  signiﬁcantly
attenuated  in  MD-2  KO  and  TLR4  KO  mice.
--  Serum  alanine  aminotransferase  was
increased  in  controls  but  was  attenuated  in
MD-2  KO  and  TLR4  KO  mice.
-- Inﬂammatory  activation,  indicated  by
serum  TNF-  and  nicotinamide  adenine
dinucleotide  phosphate  oxidase  complex
mRNA  expression  and  activation,  was
signiﬁcantly  lower  in  MCD  diet-fed  MD-2  KO
and  TLR4  KO  compared  with  corresponding
genotype  control  mice
Increased oxidative
stress  in  obesity  and
its  impact  on
Metabolic  Syndrome
Shigetada
Furukawa  et  al.
2004  Experimental
study
--  Biochemical
measurements.
--  RNA  isolation,
reverse  transcription,
and  real-time
quantitative  PCR
--  The  reactive
oxygen  species  role
was  not  determined
--  Diabetes  and  other
comorbidities  of  the
mice  model  were  not
taken  in  account  in
the  statistical
analysis
--  Production  of  ROS  increased  selectively  in
adipose  tissue  of  obese  mice,  accompanied
by  augmented  expression  of  NADPH  oxidase
and decreased  expression  of  antioxidative
enzymes
-- In  cultured  adipocytes,  elevated  levels  of
fatty acids  increased  oxidative  stress  via
NADPH  oxidase  activation,  and  oxidative
stress  caused  dysregulated  production  of
adipocytokines
-- In  obese  mice,  treatment  with  NADPH
oxidase  inhibitor  reduced  ROS  production  in
adipose  tissue,  attenuated  the
dysregulation  of  adipocytokines,  and
improved  diabetes,  hyperlipidaemia,  and
hepatic  steatosis
Main characteristics of animal and clinical studies included in the systematic revision (includes ‘‘Authors’’, ‘‘Year of publication’’, ‘‘Type of Study’’, ‘‘Methods’’, ‘‘Limitations’’ and ‘‘Main
conclusions’’.
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iIntestinal  microbiota,  Toll-like  receptors  and  metabolic  synd
functional  decrease  in  their  receptor  activity  to  only  30%
(p  =  0.0001),  and  that  they  presented  a  statistically  signiﬁ-
cant  association  with  lower  body  mass  indexes  (25.5363.50
vs.  28.6064.62  kg/m2;  age  adjusted  p  =  0.023),  waist  circum-
ferences  ((89.27614.46  vs.  97.51612.59  cm;  age  adjusted
p  =  0.025),  and  with  higher  adiponectine  levels  (14.5  ng/mL
vs.  10.6  ng/mL;  p  =  0.021).16 These  results  may  denote  a  pos-
itive  relation  between  a  prompt  activation  of  the  innate
immunity  and  obesity,  a  known  factor  present  in  Metabolic
Syndrome  patients.  These  remarkable  results,  however,
were  not  so  strongly  veriﬁed  in  the  smoking  population,
and  the  authors  point  this  factor  as  a  potential  confounding
variable  that  must  be  considered  in  future  studies.
A  strong  association  has  been  also  described  between
the  expression  and  activity  of  TLRs  and  the  development  of
type  1 and  type  2  diabetes,  major  factors  in  the  metabolic
syndrome  pathogenesis.17
A  recent  study  described  that  Tlr2−/− genotype  mice
after  12  weeks  of  high-fat  diet  not  only  had  more  glucose
tolerance  and  insulin  sensitivity  than  the  control  group,  but
also  presented  reduced  levels  of  leptin,  MCP-1  and  tumour
necrosis  factor-  (TNF-). Interestingly,  insulin  sensitivity  in
TLR2  knockout  mice  was  conserved  in  the  liver  causing  a  sig-
niﬁcant  statistical  reduction  of  hepatic  glucose  production
and  lower  risk  of  developing  hepatosteatosis  under  high-fat
diet.18 These  data  were  consistent  with  Kuo  et  al.  study
that  found  that  TLR2  knockout  mice  presented  lower  glucose
and  insulin  levels  than  their  wild  counterpart,  revealing  an
important  role  of  this  receptor  in  glucose  homeostasis.  This
same  study  also  stated  that  mice  that  knockout  to  TLR2  were
associated  to  a  phenotype  of  decreased  body  weight,  fat
mass,  lower  number  (1.21  ×  107  in  Tlr2−/− vs.  2.62  ×  107
in  WT)  and  smaller  adipocyte  cells  (mean  area  821  m2 in
Tlr2−/−  vs.  1503  m2 in  WT).19
A  meta-analysis  using  studies  that  linked  type  2  diabetes,
metabolic  syndrome  and  D299G  polymorphism  of  TLR4  also
showed  that  this  miss-sense  variant  was  responsible  for  a
lower  response  of  this  receptor  to  its  ligand,  lipopolysac-
charide,  probably  through  a  deﬁcient  recruitment  of  its
down-signalling  adapters  MyD88  and  TIR-domain-containing
adapter-inducing  interferon- (TRIF).  The  study  concluded
that  the  D299G-variant  was,  in  the  Caucasian  subgroup,
associated  to  a  reduced  risk  of  diabetes  type  2  and  metabolic
syndrome.  However  the  results  were  not  reproducible  in
other  subgroups  and  the  authors  stated  that  it  could  be
explained  by  the  differences  in  the  allele  frequency  among
different  populations.17,20
4. Microbiota and metabolic syndrome: a new
link
Recently,  the  intestinal  microbiota  has  been  progressively
studied  and  knowledge  of  its  profound  inﬂuence  in  main-
taining  the  human  physiology  and  nutrition  has  astonishingly
increased.21 Using  recent  methods  of  pyrosequencing,  the
human  gut  microbial  population  has  been  described  as
the  one  with  the  highest  in  what  concerns  to  density
and  variability  of  organisms,  comprehending  more  than
5000  bacterial  taxa  and  composed  mainly  by  Bacteroidetes
and  Firmicutes  among  other  phyla  that  are  less  preva-
lent  such  as  Actinobacteria,  Proteobacteria,  Fusobacteria,
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eferribacteres  and  Deinococcus.22 Although  the  prepon-
erant  presence  of  these  microorganisms  in  our  gut,  their
mpact  in  the  human  homeostasis  is  still  not  fully  known
nd  its  relationships  with  several  chronic  diseases,  espe-
ially  with  the  Metabolic  Syndrome,  has  opened  new  lines
f  pathological  evidence  and  potential  therapeutic  targets.
In  fact,  it  has  become  apparent  that  the  microbiota  can
hange  metabolically  the  way  we  acquire  nutrients  or  our
bility  to  harvest  energy  through  several  mechanisms.23 The
reponderance  of  these  bacteria  in  the  catalytic  processing
f  carbohydrates  in  the  human  digestion  or  even  the  pre-
ise  location  where  these  metabolic  reactions  occur  can
nﬂuence  their  availability  to  the  human  organism.23 The
acteria  are  also  associated  to  functions  such  as  stabilizing
ight  junctions  and  promoting  the  secretion  of  antiinﬂam-
atory  cytokines.23 In  the  lipid  metabolism,  several  types
f  conjugated  and  free  fatty  acids  are  generated  by  the
ntestinal  microbiota  and  play  important  roles  in  stimulat-
ng  paracrine  and  endocrine  peptides  such  as  glucagon-like
eptide  (GLP)  and  peptide  YY,  modulating  the  intestine
unction.24
Interestingly,  two  studies  by  Backhed  et  al.  compared
ice  raised  in  the  absence  of  any  microorganisms  (germ-
ree),  with  mice  in  which  was  introduced  a  microbiota  from
he  cecum  of  other  conventional  mice  raised  in  non-germ
ree  conditions,  through  a  process  that  the  authors  called
‘conventionalization’’.  Not  only  were  the  germ  free  mice
ound  to  be  resistant  to  diet-induced  obesity  even  in  low-fat
olysaccharide-rich  diet,  but  also  these  ‘‘conventionalized’’
ice  had  42%  more  total  body  fat,  which  represented  a  dra-
atic  increase  of  57%  in  their  total  body  fat  content  and
 61%  increase  in  epididymal  fat  weight,  in  spite  of  the
estern  diet  and  reduced  chow  consumption.  The  authors
lso  veriﬁed  that  these  mice  had  statistical  elevations  of
iver  mRNAs  encoding  enzymes  that  were  participants  in  the
atty  acid  biosynthetic  pathway,  leading  to  an  increase  of
riglycerides  production  in  their  livers.23,24
These  facts  point  to  inﬂuences  on  different  energetic
nputs,  nutrients  availability  and  metabolic  modulations  by
ntestinal  microbiota,  showing  an  important  contribution  to
etabolic  disturbances  similar  to  those  described  in  obesity
nd  diabetes.
Furthermore,  it  has  become  apparent  that  in  spite  of
ts  location  in  the  human  intestine,  the  microbiota  plays
mportant  systemic  changes  that  are  directly  linked  to  the
ow-grade  chronic  inﬂammatory  state,  hugely  present  in  the
etabolic  syndrome.
On  one  hand,  the  characterization  of  the  intestinal
acteria  in  obese  model  mice  (ob/ob)  was  consistent  with
0%  reduction  of  Bacteroidetes  abundance  and  a  reverse
ncrease  of  Firmicutes  when  compared  to  lean  mice.25 This
nbalanced  microbiota  was  found  to  be  modulated  by  the
omposition  of  the  diet,  mainly  rich  in  fatty  acids,  inde-
endent  of  previous  obesity  or  obese  state,  since  resistant
odels  to  high-fat  induced  obesity  mice  did  experience  the
ame  microbiome  changes  that  did  its  wild  counterpart.25
oreover,  it  was  found  that  a  high-fat  diet  simulated  the
nfusion  of  bacterial  LPS  deﬁning  a  phenotype  with  develop-
ent  of  obesity,  diabetes  and  inﬂammatory  cells  inﬁltrationn  the  adipose  tissue.  It  was  also  found  that  the  gut
acteria  were  able  to  induce  the  suppression  of  fasting-
nduced  adipocyte  factor,  thereby  limiting  the  inhibition  of
252  J.P.  Portela-Cidade  et  al.
Table  2  Principal  proposed  mechanisms  in  the  development  of  Metabolic  Syndrome  [here,  ↑  represents  an  augment  and  ↓  a
decrease].
Toll-like  receptor
activation
Biochemical  molecules
expression
Intestinal  microbiota
modiﬁcations
Phenotypical/histological
modiﬁcations
Diabetes  --  ↑  TLR4  and  TLR2
expression  levels
--  ↑  MyD88  and  TRIF
signalling  pathways
--  ↑  Insulin  levels
--  ↑  Leptin,  MCP-1  and
TNF-  expression  levels
-- ↑  CD8+  T  cells
activation  (↑  risk  of
diabetes  type  1)
--  ↑  Firmicutes  and  ↓
Bacteroidetes  and  F.
prausnitzii
--  Glucose  intolerance,  ↓
insulin  sensitivity
Dyslipidaemia  -- ↑TLR4  expression
levels
--  ↑  Saturated  Fatty
acids  and  ↓HDL
cholesterol  levels
-- ↓  Adiponectine  levels
--  ↑  Lipoprotein  lipase
and  ↓  fasting-induced
adipocyte  factor
(Angpt14/Fiaf)  activities
--  ↑  Firmicutes  and  ↓
Bacteroidetes
--  Obesity
-- Increased  macrophage
inﬁltration  in  adipose
tissue
--  Smaller  adipocytes
NASH --  ↑  TLR2  and  TLR4,  5
and  9  expression
levels
--  ↑IL-1,
phospho-interleukin-1
receptor-associated
kinase  1  and  TNF-
expression  levels
--  ↑  XBP-1,  iNOS  and
NF-kB  expression  levels
-- ↑  Nlrp3,  Nlrp6  and
IL-18  expression  levels
-- ↑MUC2  and  3  intestinal
activity
--  ↑  Firmicutes,
Porphyromonadaceae
and
Enterobacteriaceae
--  ↓Bacteroidetes,
Lactobacilli  and
Bacteroides
--  Macrovesicular  and
microvesicular  hepatic
steatosis  and
hepatocellular
ballooning
--  Obesity  and  glucose
intolerance
Metabolic
Syndrome
-- ↑  TLR2  and  TLR4
expression  levels
--  ↑IL-1,  MCP-1  and
NF-kB  expression  levels;
-- ↑  Insulin  levels  and  ↓
insulin  sensitivity
--  ↑  Firmicutes,
Desulfovibrionaceae,
and
Porphyromonadaceae
--  ↓Bacteroidetes  and
Biﬁdobacteria
--  Higher  waist
circumferences  and  body
weight
--  Diabetes  (with  all
above)
--  Dyslipidaemia  (with  all
above)
--  NASH  (with  all  above)
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iipoprotein  lipase  in  the  adipocytes  and  promoting  the  body
at  accumulation.6
Analogous  results  were  obtained  by  Remely  et  al  study,
ince  higher  prevalence  of  Firmicutes  and  lactic  bacteria
ere  encountered  in  type  2  diabetic  mice  in  opposition  to
acteroidetes  and  F.  prausnitzii. The  authors  also  tested
he  inﬂuence  of  these  population  changes  in  the  methyla-
ion  of  exons  of  TLR2  and  4  in  the  intestinal  epithelium  and
escribed  signiﬁcant  statistical  lower  methylations  rates  for
LR2  in  diabetic  mice  and  lower  methylation  rates  for  TL4  in
bese  mice,  suggesting  that  there  are  important  epigenetic
odulations  by  the  intestinal  bacteria  and  that  those  modu-
ations  could  probably  incur  in  exacerbated  risks  of  diabetes
nd  obesity.26
These  results  support  the  previous  data  from  Zhang
t  al  study  that  showed  reduced  levels  of  gut-protecting
iﬁdobacteria,  a  phylum  associated  with  resistance  to  the
ffects  of  LPS  from  the  gut  microbiota,  in  mice  with  a
igh-calorie  diet.  The  authors  suggest  that  through  the  mod-
ﬁcation  of  intestinal  microbiota  to  a  ‘‘pathogenic-like’’
b
l
f
ticrobiome,  a  high-calorie  diet  can  be  responsible  for  a  loss
f  integrity  in  the  barrier  function  of  the  intestine,  the  sys-
emic  spread  of  bacterial  endotoxins  and  pro-inﬂammatory
tate.  In  fact  the  study  points  that  a  high  inﬂammatory  state
as  present  in  all  animals  with  impaired  glucose  tolerance
nd  increased  body  fat,  on  high-fat  diet.  The  authors  also
evealed  a  predominance  of  Desulfovibrionaceae, sulphate-
educing  bacteria,  in  high-calorie  diet  mice,  a  fact  that
ould  be  related  to  the  development  of  metabolic  syndrome
n  these  mice,  since  the  disruptive  properties  of  the  sul-
hate  in  the  intestinal  barrier  were  present.  Finally,  the
uthors  described  that  this  transformation  to  a  ‘‘pathogen-
ike  population’’  through  diet,  seems  to  play  a  relevant  role
n  developing  metabolic  syndrome  that  is,  apparently,  also
ndependent  of  the  host  genetics  and  genomic  expression.27
Backhed  et  al  aimed  to  test  the  importance  of  micro-
iota  during  infancy  in  the  development  of  obesity  later  in
ife.  This  study  showed  that  breastfeeding  seems  responsible
or  the  colonization  of  the  intestine  mainly  by  Biﬁdobac-
eria  and  for  a  decrease  in  the  Enterobacteriaceae  family
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members.  The  variations  to  this  intestinal  microbiome
ecosystem,  with  reduced  levels  of  protective  strains  such  as
the  Biﬁdobacteria,  that  are  observed  in  2-year-old  infants,
had  a  profound  impact  on  a  regulator  of  the  lipopro-
tein  lipase  called  Angpt14/Fiaf,  which  seems  to  act  as  an
inhibitor  of  the  enzyme  activity  and  is  responsible  for  an
increase  in  the  body  fat  accumulation.  This  was  observed  in
studies  using  mice  models,  which  showed  an  increase  in  body
fat  tissue  not  only  in  germ-free  mice  with  Angpt14/Fiaf-
deﬁciency,  but  also  in  non-germ-free  mice,  with  a  functional
Angpt14/Fiaf  protein.
Also,  the  study  shows  that  the  use  of  antibiotics  in
infants  can  cause  the  elimination  of  Bacteroids  and  a  reduc-
tion  in  Biﬁdobacterium  population  levels,  thereby  reducing
two  important  antiobesogenic  families  in  the  intestinal
microbiota.23
5. TLR, mycrobiota and Metabolic Syndrome:
a global vision
The  activation  of  innate  immunity  through  the  TLR  cannot
be  dissociated  from  the  intestinal  microbiota  and  its  mutual
crosstalk  playing  a  decisive  factor  in  the  development  of
metabolic  syndrome.
In  fact,  the  modulation  and  interaction  between  micro-
biota  and  TLR  activation  were  investigated  in  a  TLR2
knockout  mice  study  that  revealed  that,  in  spite  of  the
genetic  predetermination  to  insulin  sensitivity  by  these  mice
reported  in  studies  before,18,19 this  phenotype  could  be  dras-
tically  reversed  by  gut  microbiota.  The  study  conﬁrmed  that
these  TLR2  knockout  mice,  in  non-germ-free  facilities,  had
higher  levels  of  Firmicutes  and  Bacteroidetes  in  compari-
son  to  wild-type  mice,  and  increased  lipopolysaccharides
absorption,  glucose  intolerance,  insulin  resistance  and  obe-
sity.  The  authors  stated  that  these  results  can  be  explained
by  an  increased  activation  of  TLR4  receptors  in  the  absence
of  TLR2  activation.  They  also  veriﬁed  increased  endoplas-
mic  reticulum  stress  and  JNK  activation  by  the  TLR4,  which
had  effects  that  could  be  inhibited  by  a  TLR4  antisense
oligonucleotide  causing  an  increase  in  glucose  tolerance  and
sensitivity  when  compared  to  the  controls.  Furthermore,
in  TLR2  knockout  mice,  the  use  of  a  mixture  of  antibi-
otics  resulted  in  an  improvement  of  insulin  sensitivity  and
metabolic  status.7
Another  recent  study  by  Ubeda  et  al  further  revealed
that  using  knock-out  mice  to  a  speciﬁc  TLR,  the  impact
of  the  absence  of  that  certain  TLR  was  initially  minimal  in
the  bacteria  communities  at  the  intestine,  after  a  treat-
ment  with  antibiotics,  when  compared  to  their  respective
wild-type  mice.  This  evidences  that  some  caution  is  advised
when  valorizing  microbial  communities’  differences  in  these
groups.  Interestingly,  the  authors  also  stated  that  differ-
ences  in  mice’s  colonies  with  different  TLR  deﬁciencies
were  only  veriﬁed  after  long-term  breeding  in  isolation  from
each  other,  and  probably  with  great  inﬂuence  from  maternal
transmission.28 However,  contrary  to  the  previous  study  of
Vijay-Kumar  et  al29 that  described  a  major  link  between  TLR-
5  KO  mice  and  the  development  of  metabolic  syndrome,  this
study  did  not  ﬁnd  any  difference  in  the  intestinal  microbiota
colonies  or  in  the  risk  of  metabolic  syndrome.  The  authors
d
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ttribute  these  results  to  differential  exposures  in  husbandry
onditions  and  mice  types.28
To  add  to  this  complex  network  of  relations  between
ost  genetic  expression  and  the  environment,  Kellermayer
t  al.  study  showed  an  increased  risk  of  epigenetic  modiﬁca-
ion,  DNA  methylation  and  differential  rates  of  transcripts
n  TLR2-knockout  mice  in  the  intestinal  mucosa  epithe-
ium.  The  authors  pointed  out  that  these  epigenetics  and
etagenomic  effects,  along  with  the  modulation  of  the
acterial  populations,  could  explain  the  loss  of  the  pro-
ective  barrier  function  of  the  intestine  and  changes  in
he  microbiome  environment  observed  in  the  Metabolic
yndrome.30
As  the  importance  of  the  intestinal  microbiome  in  the
etabolic  syndrome  becomes  more  apparent,  new  lines  of
nvestigation  have  appeared,  aiming  the  bacterial  popula-
ions  as  a  therapeutic  hypothesis  in  the  Metabolic  Syndrome.
A  study  by  Wang  et  al  used  high-fat  diet  mice  in  which
as  induced  metabolic  syndrome  and  subjected  them  to
dministration  of  one  of  three  probiotics  (Lactobacillus
aracasei,  L.  rhamnosus  and  Biﬁdobacterium  animalis)  in
rder  to  modulate  the  gut  microbiota.  The  results  showed
hat  these  strains  were  able  to  reduce  the  weight  gain,
ncrease  insulin  sensitivity  and  limit  hepatic  steatosis,  and
lso  that  they  were  able  to  modulate  innate  immunity  and
he  pro-inﬂammatory  state,  through  the  reduced  inﬁltration
f  macrophages  in  the  adipose  tissue.  Moreover,  the  probio-
ic  treatment  was  capable  of  reducing  key  phylotypes  keen
o  cause  metabolic  syndrome  (as  are  Desulfovibrionaceae
nd  Clostridium  examples),  and  capable  of  reducing  inﬂam-
atory  processes  associated  to  sulphate  sodium-induced
esion  by  these  bacteria.  On  the  other  hand,  certain  strains
nd  also  certain  combinations  of  probiotic  strains  can  prob-
bly  provide  different  beneﬁts  in  reversing  the  metabolic
yndrome  by  a different  impact  on  certain  mechanisms,
uch  as  the  increase  of  acetate,  a known  molecule  shown
o  be  able  to  improve  obesity  and  diabetes  on  these
ice.31
Another  study,  performed  in  humans,  reported  that  infu-
ion  of  intestinal  microbiota  collected  from  lean  donors  into
he  intestine  of  Metabolic  Syndrome  subjects  was  able  to
ncrease  insulin  sensitivity  (median  rate  of  glucose  disap-
earance  changed  from  26.2  to  45.3  mol/kg/min;  p  <  0.05),
fter  6  weeks.  These  changes  were  associated  to  an  increase
f  butyrate-producing  bacteria  in  the  gut’s  recipients,  which
s  known  to  inﬂuence  directly  the  glucose  metabolism.32
nother  study  using  probiotics  rich  in  Lactobacillus  veri-
ed  that  those  who  received  the  probiotics  had  lower  body
ass  index,  waist  and  hip  measurements,  and  presented  a
eduction  of  fat  in  the  abdomen  and  subcutaneous  areas
p  <  0.01).32
A  randomized  pilot  study  by  Leber  et  al.  tried  to  unravel
he  effect  of  a  Lactobacillus  probiotic  strain  in  the  gut
ermeability  and  bacterial  endotoxin  presence,  in  human
etabolic  syndrome  patients,  covering  two  phenomena
ttributed  to  the  pathogenesis  of  the  syndrome.  However,
n  spite  of  the  signiﬁcant  increase  of  the  gut  permeability  in
he  metabolic  syndrome  group  of  patients,  the  investigators
id  not  ﬁnd  any  difference  of  the  endotoxin,  C-reactive  pro-
ein,  neutrophil  function  and  TLR  expression  levels  between
he  group  who  had  received  the  probiotic  and  the  control
roup.33
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. Liver as a pivotal organ in metabolic
yndrome
he  liver  is  a  major  organ  of  the  human  organism  and  it  has  a
rofound  impact  in  its  metabolic  and  immune  homeostasis.10
ndeed,  its’  high  efﬁcient  metabolic  regulation  of  glucose,
atty  acids  and  immune  regulators  and  its  privileged  location
s  an  organ  that  ﬁrst  receives  blood  from  the  gastrointestinal
ract,  protecting  the  remaining  circulation  from  its  poten-
ial  threats,  makes  the  liver  a  crucial  participant  in  several
egulatory  processes.  Furthermore  it  has  been  progressively
eriﬁed  that  these  same  functions  can  be  unbalanced  in  the
etabolic  syndrome.  In  fact,  a  prompt  activation  of  several
mmune  receptors  on  the  hepatic  immune  system  occurs  in
esponse  to  a  break  of  the  intestinal  epithelial  barrier  func-
ion  and  to  an  increase  of  certain  bacterial  populations  and
heir  translocation  through  the  vascular  system.10
Therefore,  this  immune  mechanism  to  disrupted  intesti-
al  homeostasis  can  explain  the  development  of  non-
lcoholic  fatty  liver  disease  the  development  of  several
omorbidities  such  as  diabetes,  dyslipidaemia  and  obesity,
nd  its  increased  risk  to  metabolic  syndrome.1
Sawada  et  al  aimed  to  measure  the  expression  of  TLRs,
NF-, interleukin-1B  and  phospho-interleukin-1  receptor-
ssociated  kinase  1,  in  the  liver  and  small  intestine,  in
on-alcoholic  fatty  liver  disease  induced  mice.  The  authors
eported  a  signiﬁcant  statistical  increase  in  the  inﬂamma-
ory  cytokines  and  TLR2,  4,  5  and  9  expressions  in  the  liver
f  16-week  mice,  but  no  differences  in  the  liver  of  4-  and
-week  mice.  The  study  also  revealed  that,  in  the  intestine,
xactly  the  opposite  could  be  observed,  since  all  parameters
ere  signiﬁcantly  decreased  indicating  that  these  pathways
re  probably  inhibited  in  mice  with  NAFLD.  Moreover,  the
reatment  of  these  mice  with  antibiotics  could  attenuate
he  higher  expression  of  those  inﬂammatory  markers  and
LRs  in  the  liver  but  it  had  little  impact  on  the  expression
f  these  molecules  in  the  small  intestine  of  NAFLD  mice.34
The  authors  further  stated  that,  the  increase  on  the
iver  TLRs  expression  appears  to  be  selective  since  TLR2,
,  5  and  9  were  upregulated  in  primary  Kupffer  cells  while
nly  TLR4  and  9  were  increasingly  expressed  in  the  primary
epatocytes.34
Another  recent  study  tested  the  effect  of  TLR4  in  NASH
n  high-fat,  high-cholesterol  diet  mice.  The  results  stated
hat,  compared  with  wild-type,  the  TLR4  mutated  mice
ere  resistant  to  the  development  of  macrovesicular  and
icrovesicular  steatosis,  hepatocellular  ballooning  and  a
vefold  increase  in  NASH  scores.  This  phenotype  was  even
ssociated  to  a  decreased  TLR4  function  mainly  in  Kupffer
ells,  and  consequential  lower  levels  of  macrophages  and
ytokines.  Interestingly,  the  study  also  included  the  mea-
urement  of  a  transcription  factor  named  XBP-1,  known
o  be  stimulated  by  reactive  oxygen  species  and  a  part
f  the  responsive  pathway  to  that  oxidative  stress  through
he  unfolded  protein  response  cascade.  This  protein  was
brogated  in  the  TLR4  mutant  mice,  with  a  simultaneously
ecrease  of  NF-kB  activation  and  cytokine  production.35Also,  TLR4  has  been  described  as  a  signalling  way  to
AFLD  development,  in  high-fat  diet  mice,  and  linked  to
epatic  steatosis,  hepatic  insulin  resistance  and  hepatic
eight  gain  in  these  experimental  circumstances.  The  same
F
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esults  were  found  through  other  members  of  TLR  family
uch  as  TLR9  and  TLR5  pathways.36 Finally  TLR2  was  also
tudied  and  is  now  apparent  that  its  ligands  are  increased  in
bese  mice  and  that  its  blockage  can  restrain  its  insulin  resis-
ance  induction.  In  fact,  TLR2  knockout  mice  exhibit  lower
xpression  of  TNF- and  IL-1 inﬂammatory  cytokines.19
The  same  rational  was  presented  in  other  studies,  where
ructose-induced  hepatic  steatosis  in  mice  was  associated
ith  signiﬁcant  induction  of  TLR1-4  and  TLR6-8  along  with  an
ncrease  of  MyD88,  TNF-  and  iNOS  levels.  The  authors  point
ut  that  bacterial  components  translocation  and  the  prompt
ctivation  of  TLRs  and  TLR-dependent  pathways  support  a
hronic  inﬂammatory  state  that  could,  in  the  liver,  end  with
he  development  of  non-alcoholic  liver  disease.29,33,37
Further  studying  the  participation  of  the  inﬂammasome
athway  in  the  NAFLD  pathology,  Henao-Mejia  et  al  tested
wo  inﬂammasome  molecules  and  its  effector  protein  in  bac-
erial  modulation  and  metabolic  syndrome  outcome.  The
tudy  revealed  that  the  progress  from  NAFLD  to  NASH  was
ositively  inﬂuenced  by  these  molecules  since  knockout
ice  to  inﬂammasome  proteins  (Nlrp3  and  Nlrp6)  were  asso-
iated  to  lower  effector  protein  (IL-18)  levels,  different  gut
icrobiota  and  increased  TLR4  and  TLR9  agonists.  These
ice  also  had  more  hepatic  steatosis,  obesity  and  glucose
ntolerance  and  higher  rate  of  Porphyromonadaceae  in  the
ntestinal  gut,  a  known  bacterial  family  that  increases  the
isk  of  metabolic  syndrome  in  both  mice  and  humans.38
Considering  its  importance,  a  modulation  by  probiotics
an  emerge  as  a  therapeutic  target  to  this  ‘‘metabolic
nfection’’.  A recent  study  by  Liang  et  al.  using  probiotics
howed  an  improvement  in  the  obesity,  glucose  tolerance
nd  insulin  levels  in  high-fat  diet-fed  mice.  It  also  revealed
hat  hepatic  steatosis  was  reduced  with  signiﬁcantly  lower
epatic  triglyceride  content  and  improved  histology,  with
he  use  of  this  probiotics.39
Another  study  by  Xie  et  al  used  normal  and  liver  cir-
hosis  mice  that  were  subjected  to  liver  transplantation.
he  authors  found  that  not  only  the  liver  cirrhosis  groups
ad  higher  endotoxin  levels  and  higher  numbers  of  total
acteria,  but  also,  the  referred  group  had  an  increased
umber  of  bacteria  in  liver  and  lymph  nodes.  The  liver  cir-
hosis  groups  had  higher  rates  of  Enterobacteriaceae  and
ower  Lactobacilli  and  Bacteroides  and,  simultaneously,  had
igher  MUC2,  MUC3  and  TLR2  and  4  mRNA  expression  lev-
ls  in  the  intestine  epithelium,  and  TLR2  and  4  increased
RNA  expression  levels  in  the  liver.  Astonishingly,  these
arameters  had  not  improved  until  1  month  after  the  liver
ransplantation  and,  surprisingly,  had  not  improved  with  the
se  of  a  lactobacillus-enriched  probiotic,  suggesting  prob-
bly  the  need  of  longer  times  of  therapy  or  search  for
ifferent  probiotic  compositions  speciﬁc  for  each  metabolic
evel  of  disturbance,  either  hepatic  or  systemic.40 This  ratio-
al  may  account  for  important  medical  decisions  in  the
uture  and  possibly  allow  different  therapeutical  options
ecome  medically  used  in  clinical  practice.
. Discussionor  all  the  data  stated,  it  is  well  apparent  that  the  interac-
ion  between  intestinal  microbiota  and  the  innate  immunity
ight  have  a  pivotal  role  in  the  metabolic  syndrome,  which
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- Activ ation of  TLR and higher e xpression of inflammator y cytokines, NF-Kb ,
TNF-alfa and inter leucin 1bet a
- Transfor mation of hepatic tissue in non-alcoholic steatohepatitis and
cirrhosis
- Higher activation of TLR and MUC
- Loss of barrier function of the intestine and
bacterial translocation
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Figure  2  Consequences  and  inﬂammatory  pathways  activated  during  the  development  of  metabolic  syndrome  in  intestinal  and
liver tissues.  The  prompt  activation  in  the  intestinal  epithelium  by  intestinal  microbiota  leads  to  an  activation  of  Myd88  signalling
pathways, with  higher  mRNA  expression  of  TLR2,  4,  5  and  9,  inﬂammatory  cytokines,  TNF-,  interleucin  1  and  MUC  2  and  3
receptors. This  causes  a  loss  barrier  function  of  the  intestine  and  bacterial  translocation  to  other  organs  especially  the  liver.  In  the
liver occurs  Myd88  signalling  pathways  activation  with  increased  mRNA  expression  of  TLR2,  4,  5,  6  and  9  in  hepatocyte  and  Kupffer
cells. The  increased  expression  of  inﬂammatory  cytokines,  NF-Kb,  TNF-  and  interleucin-1  and  decrease  in  anti-inﬂammatory
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gpathways as  XBP-1  culminating  in  transformation  of  hepatic  tissu
had  impact  that  could  go  way  beyond  the  limits  of  the  intes-
tine  and  have  a  direct  and  systemic  impact  through  several
organs  (Table  2).
Based  on  the  results  analyzed,  we  propose  that  the
composition  of  the  intestinal  microbiome,  changing  from  a
‘‘symbiotic’’  population  mainly  composed  by  Biﬁdobacte-
ria  and  Bacteroidetes,  to  a  more  ‘‘unbalanced’’  one,  where
Firmicutes,  Porphyromonadaceae  and  Desulfovibrionaceae
emerge,  can  be  modulated  and  provoked  by  diet  and  its  rel-
ative  composition  in  lipids  and  other  factors.  This  dysbiotic
environment  can  promptly  activate  several  immune  recep-
tors  present  in  the  intestinal  barrier  though  the  recognition
of  PAMPs  and  bacterial  antigens,  culminating  in  an  increased
activation  of  TLR2,  4,  5  and  9,  and  other  synergic  inﬂam-
matory  signalling  pathways  that  were  not  described  yet.
The  local  pro-inﬂammatory  proﬁle  can  explain  the  altered
phenotypic  expression  of  these  receptors  at  the  intestine
surface,  the  metabolic  absorption  disturbances  observed,
the  increase  of  cytokines  and  inﬂammatory  markers  levels
and  the  loss  of  barrier  function  of  the  intestine,  which  are
all  described  in  metabolic  syndrome  models.41,42
With  this  break  of  intestine  mechanic  defences,  this  dys-
biotic  bacteria  and  its  products  will  have  an  easy  access  to
a
r
m
Mto  non-alcoholic  steatohepatitis  and  cirrhosis  are  also  relevant.
he  vascular  space,  raising  the  level  of  exogenous  provoca-
ive  antigens  to  the  immune  innate  system  and  through  its
ranslocation  inﬂuence  the  homeostasis  of  different  organs,
pecially  the  liver  because  of  its  metabolic  preponderance
nd  privileged  location43 (Fig.  2).
These  mechanisms  synergistically  account  for  the
ncreased  activation  of  TLR2,  4,  5  and  9  in  the  Kupffer
ells  and  the  TLR2,  4  and  9  in  the  hepatocytes  and  the
onsequential  increase  in  the  inﬂammatory  products  of  its
athways  such  as  TNF-, IL-1 and  iNOS.  This  chronic  inﬂam-
atory  state  can  justify  the  appearance  of  macrovesicular
nd  microvesicular  steatosis,  and  hepatocellular  ballooning
hat  counts  for  the  NASH  transformation.44 The  role  and
verexpression  of  several  other  molecules  as  xBP1  and  NFKb
an  further  explain  this  modiﬁcation  probably  through  a  shift
n  the  genetic  expression  and/or  epigenetic  modulation  of
he  liver  cells.
On the  other  hand,  throughout  the  organism,  the  anti-
enic  activation  of  TLR2  and  TLR4  in  various  cells  can  be major  way  of  explaining  the  glucose  intolerance,  insulin
esistance  and  the  increased  risk  of  diabetes,  and  co-
orbidity  associated  to  this  syndrome.  Furthermore,  the
yD88  pathway  activated  by  these  receptors  seems  to  be
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Figure  3  Consequences  and  inﬂammatory  pathways  activated  during  the  development  of  metabolic  syndrome  in  adipose  and
other tissues.  Present  in  the  metabolic  syndrome  development  are  increased  mRNA  expression  of  TLR4  and  inﬂammatory  cytokines
and decreased  adiponectine  production  and  lipoprotein  lipase,  in  the  adipose  tissue.  A  macrophage  invasion  and  inﬂammatory
pathways activation  within  this  tissue  are  also  present.  Systemically  a  prompt  activation  of  Myd88  signalling  pathways  also  occurs
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tith mRNA  expression  of  TLR2  and  4  and  inﬂammatory  cytoki
ensitivity throughout  the  human  organism.
reponderant  to  this  outcome,  since  the  absence  of  its
ignalling  participants  or  TRIF  could  account  for  a  reduced
isk  of  diabetes  developed.5
The  innate  immunity  activation  can  even  inﬂuence  the
ilieu  of  the  adipose  tissue,  being  responsible  for  a  pro-
nﬂammatory  state  with  increased  activation  of  TLR4,  the
ecruitment  of  different  inﬂammatory  cells  and  the  produc-
ion  of  inﬂammatory  molecules.  This  can  be  the  cause  of
he  decreased  adiponectine  levels  expression,  the  increased
ipoprotein  lipase  functions  and  the  explanation  of  the  dys-
ipidaemia  and  obesity  present  in  these  patients45 (Fig.  3).
Furthermore,  the  chronic  inﬂammatory  state  is  known  to
isturb  the  balance  of  coagulation/anticoagulation  factors
nd  the  metabolic  production  of  oxidative  stress  throughout
he  organism.  These  factors  can  further  inﬂuence  the  regu-
ation  of  delivering  nutrients  and  energetic  substrates  to  the
ells  and  its  internal  management,  causing  a  most  profound
mpact  in  the  homeostatic  equilibrium  of  the  human  body.46
These  new  data  open  interesting  lines  of  evidence  that
 modulation  of  intestinal  microbiota  can  be  a  powerful
e
d
a
ahat  globally  causes  glucose  intolerance  and  decreased  insulin
herapeutic  way  of  inﬂuence  or  even  reverse  the  progres-
ion  of  metabolic  syndrome.  The  use  of  probiotics  has
evealed  that  through  changes  in  the  intestinal  dysbiosis,  a
ower  pro-inﬂammatory  proﬁle  can  be  achieved  with  expres-
ive  beneﬁts  in  glucose  tolerance,  insulin  sensitivity,  lower
eight  and  lower  hepatic  steatosis.  Although  several  lines
f  investigation  are  still  needed  on  this  behalf,  the  data
ollected  so  far  are  consistent  with  a  potential  therapeutic
arget  in  the  clinical  control  of  metabolic  syndrome  devel-
pment  and  treatment.47
In  conclusion,  this  review  detects  several  lines  of  evi-
ence  of  the  profound  preponderance  of  early  activation  of
LR  receptors  and  its  interactions  with  a  dysbiotic  intesti-
al  microbiota  in  causing  several  disturbances  known  to  be
mplicated  in  metabolic  syndrome.  Thus,  in  the  near  future,
he  understanding  if  there  is  a  speciﬁc  set  of  TLR  over-
xpression  associated  to  the  different  chronic  metabolic
iseases  that  coexist  in  the  metabolic  syndrome,  the  char-
cterization  of  the  modulation  of  hepatic  immune  receptors
nd  cytokine  production  and  the  clariﬁcation  of  which  are
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the  major  bacterial  molecules  that  work  as  a  factor  to  prop-
agate  or  ameliorate  the  metabolic  syndrome  state,  shall  be
preponderant  points  in  the  breakthrough  of  the  investigation
in  metabolic  syndrome  medical  area.
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